Drug Profile

ANB 033

Alternative Names: ANB-033

Latest Information Update: 20 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AnaptysBio
Developer First Tracks Biotherapeutics
Class Anti-inflammatories; Immunotherapies; Monoclonal antibodies
Mechanism of Action Interleukin-2 receptor beta subunit antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Autoimmune disorders; Coeliac disease; Eosinophilic oesophagitis

Most Recent Events

13 Aug 2026 First Tracks Biotherapeutics plans to initiate phase II trials in two additional indications in H1 2027
12 Aug 2026 US FDA grants fast track designation for ANB 033 for Celiac disease, prior to August 2026
08 Apr 2026 Phase-I clinical trials in Coeliac disease in Australia (SC) prior to April 2026 (ISRCTN16318446)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com